MolecularMD Enters Into a Collaboration Agreement With Illumina for Drug-Diagnostic Co-Development With Biopharma Drug Programs


PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - June 27, 2016) - MolecularMD Corporation announced today that it has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN) that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics in support of biopharma drug development program(s). The agreement dovetails MolecularMD's companion diagnostic development and FDA submission experience with Illumina's NGS technology.

"This agreement is designed to deliver the combined power of Illumina's NGS technologies with MolecularMD's ability to tailor a complete clinical development solution including regulatory planning, IDE validations and centralized testing and data management for global patient enrollment and disease monitoring," stated Dan Snyder, CEO of MolecularMD.

MolecularMD opened its advanced diagnostic laboratory in Cambridge, MA in 2012 with the objective of providing NGS solutions that support clinical trials of oncology drug programs. MolecularMD has since deployed NGS diagnostics over a broad range of drug targets and indications. The ability to support global trials with centralized testing laboratories while simultaneously obtaining necessary regulatory compliance can allow rapid deployment of Illumina based NGS solutions.

"Our goal is to enable our clients with the latest platforms and proven technologies that solve for the challenges that often arise during drug and diagnostic co-development," stated Snyder. "The ability to collaborate with Illumina on defined projects will greatly aid our clients to mitigate risks and to accelerate their clinical trial programs."

About MolecularMD

MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents.

Contact Information:

Media Inquiries:
Tina Beauchemin
MolecularMD
(617) 575-2824 x613
tbeauchemin@molecularmd.com